IFF Reports Second Quarter 2024 Results
IFF reported second quarter 2024 results with sales of $2.9B and adjusted operating EBITDA of $588M. The company saw a 7% increase in comparable currency neutral sales led by growth in Scent, Health & Biosciences, and Nourish segments. Adjusted EPS excluding amortization was $1.16 per diluted share. IFF is raising its full-year 2024 guidance, now expecting sales between $11.1B to $11.3B and adjusted operating EBITDA of $2.1B to $2.17B. The company projects volume growth of 3% to 5% across most of its portfolio. CEO Erik Fyrwald expressed satisfaction with the company's performance, citing improvements in volume growth and productivity initiatives.
IFF ha riportato i risultati del secondo trimestre 2024 con vendite di 2,9 miliardi di dollari e un EBITDA operativo rettificato di 588 milioni di dollari. L'azienda ha registrato un aumento del 7% nelle vendite comparabili a valuta costante, guidato dalla crescita nei segmenti Fragranze, Salute e Bioscienze, e Nutrizione. L'EPS rettificato escludendo l'ammortamento è stato di 1,16 dollari per azione diluita. IFF sta alzando le previsioni per l'intero anno 2024, ora prevedendo vendite tra 11,1 miliardi e 11,3 miliardi di dollari e un EBITDA operativo rettificato di 2,1 miliardi a 2,17 miliardi di dollari. L'azienda prevede un crescita del volume del 3% al 5% su gran parte del suo portafoglio. Il CEO Erik Fyrwald ha espresso soddisfazione per le performance dell'azienda, citando i miglioramenti nella crescita del volume e le iniziative di produttività.
IFF reportó los resultados del segundo trimestre de 2024 con ventas de 2.9 mil millones de dólares y un EBITDA operativo ajustado de 588 millones de dólares. La compañía vio un aumento del 7% en las ventas comparables a moneda constante, impulsado por el crecimiento en los segmentos de Fragancias, Salud y Biosciencias, y Nutrición. El EPS ajustado excluyendo la amortización fue de 1.16 dólares por acción diluida. IFF está elevando su guía para el año completo de 2024, ahora esperando ventas entre 11.1 mil millones y 11.3 mil millones de dólares y un EBITDA operativo ajustado de 2.1 mil millones a 2.17 mil millones de dólares. La compañía proyecta un crecimiento del volumen del 3% al 5% en la mayor parte de su portafolio. El CEO Erik Fyrwald expresó satisfacción por el desempeño de la compañía, citando mejoras en el crecimiento del volumen y las iniciativas de productividad.
IFF는 2024년 2분기 실적을 보고했으며, 매출은 29억 달러, 조정 운영 EBITDA는 5억 8,800만 달러였습니다. 이 회사는 향수, 건강 및 생명 과학, 영양 부문에서의 성장이 이끌어낸 비교 가능한 통화 기준 매출 7% 증가를 보았습니다. 상각비를 제외한 조정 EPS는 희석 주당 1.16 달러였습니다. IFF는 2024년 전체 연도 가이드를 상향 조정하고 있습니다, 이제 111억 달러에서 113억 달러 사이의 매출과 21억 달러에서 21억 7천만 달러의 조정 운영 EBITDA를 예측하고 있습니다. 이 회사는 포트폴리오 대부분에 대해 3%에서 5%의 볼륨 성장을 프로젝트하고 있습니다. CEO Erik Fyrwald는 회사의 성과에 만족감을 표현하며, 볼륨 성장과 생산성 이니셔티브의 개선을 언급했습니다.
IFF a rapporté les résultats du deuxième trimestre 2024 avec des ventes de 2,9 milliards de dollars et un EBITDA opérationnel ajusté de 588 millions de dollars. L'entreprise a enregistré une augmentation de 7% des ventes comparables en monnaie constante, propulsée par la croissance des segments Parfum, Santé et Biosciences, et Nutrition. Le BPA ajusté hors amortissement était de 1,16 dollar par action diluée. IFF augmente ses prévisions pour l'année entière 2024, s'attendant désormais à des ventes entre 11,1 milliards et 11,3 milliards de dollars et un EBITDA opérationnel ajusté de 2,1 milliards à 2,17 milliards de dollars. L'entreprise projette une croissance du volume de 3% à 5% dans la plupart de son portefeuille. Le PDG Erik Fyrwald a exprimé sa satisfaction quant à la performance de l'entreprise, citant des améliorations dans la croissance du volume et les initiatives de productivité.
IFF berichtet über die Ergebnisse des zweiten Quartals 2024 mit einem Umsatz von 2,9 Milliarden USD und einem angepassten operativen EBITDA von 588 Millionen USD. Das Unternehmen verzeichnete einen Umsatzanstieg von 7% bei vergleichbaren, währungsbereinigten Verkäufen, der durch das Wachstum in den Segmenten Düfte, Gesundheit & Biosciences sowie Ernährung gesteuert wurde. Das ajustierte EPS ohne Amortisation betrug 1,16 USD pro verwässerter Aktie. IFF erhöht seine Gesamtprognose für das Jahr 2024 und erwartet nun einen Umsatz zwischen 11,1 Milliarden und 11,3 Milliarden USD sowie ein angepasstes operatives EBITDA von 2,1 Milliarden bis 2,17 Milliarden USD. Das Unternehmen rechnet mit einem Volumenwachstum von 3% bis 5% in den meisten Bereichen seines Portfolios. CEO Erik Fyrwald äußerte Zufriedenheit mit der Unternehmensleistung und verwies auf Verbesserungen beim Volumenwachstum und bei Produktivitätsinitiativen.
- 7% increase in comparable currency neutral sales
- 22% improvement in comparable adjusted operating EBITDA
- Raised full-year 2024 sales and adjusted operating EBITDA guidance
- Projected volume growth of 3% to 5% across most of the portfolio
- Strong performance in Scent segment with 16% comparable currency neutral sales growth
- Health & Biosciences segment saw 9% comparable currency neutral sales growth
- 1% decrease in reported net sales compared to the prior-year period
- Pharma Solutions segment experienced a 19% decline in comparable adjusted operating EBITDA
- Expected 3% to 4% adverse impact on sales growth due to foreign exchange rates
- Net debt to credit adjusted EBITDA ratio at 4.0x
IFF's Q2 2024 results show a mixed performance with some positive trends. Sales decreased
Key positives include volume growth across most segments and improved productivity. The Scent segment particularly stood out with a
The company's raised guidance for full-year 2024 is encouraging, now expecting sales of
Investors should note the high debt levels, with net debt to credit adjusted EBITDA at 4.0x, which could be a concern if economic conditions worsen.
IFF's Q2 results reflect a gradual recovery in the fragrance and flavor markets. The strong performance in Consumer Fragrance and Flavors suggests improving consumer demand. The
The company's strategic focus on R&D and commercial efforts in key growth areas is promising. Increased investments in digital systems could enhance operational efficiency and customer engagement. However, the challenges in Functional Ingredients and Pharma Solutions highlight the need for continued portfolio optimization.
The raised volume growth forecast of
Second Quarter 2024 Consolidated Summary:
Reported
|
|
Adjusted
|
||||||||
Sales |
|
Income Before
|
|
EPS |
|
Operating
|
|
Operating
|
|
EPS ex
|
|
|
|
|
|
|
|
|
|
|
|
First Six Months 2024 Consolidated Summary:
Reported
|
|
Adjusted
|
||||||||
Sales |
|
Income Before
|
|
EPS |
|
Operating
|
|
Operating
|
|
EPS ex
|
|
|
|
|
|
|
|
|
|
|
|
Management Commentary
"We are pleased with our performance through the first half of the year, as it represents a marked improvement over our prior year lows," said IFF CEO Erik Fyrwald. "Our efforts to drive volume growth across all our business units, combined with enhanced productivity initiatives, have resulted in solid profit improvements compared to the same period last year. Given our performance to date and our cautiously optimistic outlook for the remainder of the year, we are raising both our sales and adjusted operating EBITDA guidance for the full year."
"We are energized by the progress we are making in the development of our customer focused and innovation led strategy. The entire IFF team is rallying behind this strategic refresh, and while we still have more work to do, we have identified significant growth opportunities. We have started to increase our investments in R&D, commercial efforts, and capacity in flavors, scent, and health and biosciences as well as increasing investments to strengthen our digital systems. At the same time, we are rapidly addressing our functional ingredients business by implementing additional productivity initiatives to improve our margin while we target attractive customer segments. We believe these actions will deliver stronger value creation for our customers, employees, and shareholders over time."
Second Quarter 2024 Consolidated Financial Results
-
Reported net sales for the second quarter were
$2.89 billion 1% versus the prior-year period. On a comparable basis2, currency neutral sales1 increased7% versus the prior-year period led by growth in Scent, Health & Biosciences and Nourish. Volume grew high-single digits and continued to improve sequentially across nearly all businesses. -
Income before taxes on a reported basis for the second quarter was
$183 million $588 million 22% versus the prior-year period, led by volume growth and productivity gains. -
Reported earnings per share (EPS) for the second quarter was
$0.66 $1.16 -
Cash flows from operations at the end of the second quarter was
$336 million $136 million
Second Quarter 2024 Segment Summary: Growth vs. Prior Year
|
Reported (GAAP) |
|
Comparable
|
|
Adjusted
|
|
Comparable
|
|
Sales |
|
Sales |
|
Operating EBITDA |
|
Operating EBITDA |
Nourish |
(5)% |
|
|
|
|
|
|
Health & Biosciences |
|
|
|
|
|
|
|
Scent |
|
|
|
|
|
|
|
Pharma Solutions |
|
|
|
|
(19)% |
|
(19)% |
Nourish Segment
-
On a reported basis, second quarter sales were
$1.48 billion 4% driven by double-digit growth in Flavors. Functional Ingredients performance continued to improve sequentially and delivered high-single digit volume growth, yet sales declined low-single digits against the year-ago period as a result of pricing actions. -
Nourish adjusted operating EBITDA1 was
$232 million 15.7% in the second quarter. On a comparable basis2, adjusted operating EBITDA1 increased36% led by volume growth, productivity gains and the benefit of the Locust Bean Kernel write-down in the prior year period.
Health & Biosciences Segment
-
On a reported basis, second quarter sales were
$558 million 9% driven by strong performances across all businesses. Health also returned to growth driven by a strong performance in Probiotics. -
Health & Biosciences adjusted operating EBITDA1 was
$165 million 29.6% in the second quarter. On a comparable basis2, adjusted operating EBITDA1 improved14% led by volume growth and productivity gains.
Scent Segment
-
On a reported basis, second quarter sales were
$603 million 16% led by strong double-digit growth in Consumer Fragrance and Fragrance Ingredients as well as a mid-single digit increase in Fine Fragrance. -
Scent adjusted operating EBITDA1 was
$137 million 22.7% in the second quarter. On a comparable basis2, adjusted operating EBITDA1 increased38% led primarily by volume growth and productivity gains.
Pharma Solutions Segment
-
On a reported basis, second quarter sales were
$250 million 0% as a return to volume growth was offset by modestly lower pricing. -
Pharma Solutions adjusted operating EBITDA1 was
$54 million 21.6% in the second quarter. On a comparable basis2, adjusted operating EBITDA1 declined19% which was according to plan as volume growth and productivity gains were more than offset primarily by unfavorable mix and one-time items.
Financial Guidance
The Company is increasing its expectations for the full year 2024 and now expects full year 2024 sales to be in the range of
Based on current market foreign exchange rates, the Company expects that foreign exchange will have a
The Company cannot reconcile its expected adjusted operating EBITDA without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include but are not limited to acquisition, divestiture and integration related costs, gains (losses) on business disposals and regulatory costs.
Audio Webcast
A live webcast to discuss the Company’s second quarter 2024 financial results will be held on August 7, 2024, at 9:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event and will remain available on IFF’s website for one year.
Cautionary Statement Under The Private Securities Litigation Reform Act of 1995
Statements in this press release, which are not historical facts or information, are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations including those concerning expected cash flow and availability of capital resources to fund our operations and meet our debt service requirements; our ability to execute on our strategic and financial transformation, including the progress and success of our portfolio optimization strategy (including the sale process for our Pharma Solutions disposal group), through non-core business divestitures and acquisitions, and expectations regarding the implementation of our refreshed growth-focused strategy and expectations around our business divestitures; our ability to continue to generate value for, and return cash to, our shareholders; expectations of the impact of inflationary pressures and the pricing actions to offset exposure to such impacts; the impact of high input costs, including commodities, raw materials, transportation and energy; the expected impact of global supply chain challenges; our ability to enhance our innovation efforts, drive cost efficiencies and execute on specific consumer trends and demands; the growth potential of the markets in which we operate, including the emerging markets; expectations regarding sales and profit for the fiscal year 2024, including the impact of foreign exchange, pricing actions, raw materials, energy, and sourcing, logistics and manufacturing costs; the impact of global economic uncertainty and recessionary pressures on demand for consumer products; the success of our integration efforts, following the N&B Transaction, and ability to deliver on our synergy commitments as well as future opportunities for the combined company; our strategic investments in capacity and increasing inventory to drive improved profitability; our ability to drive cost discipline measures and the ability to recover margin to pre-inflation levels; expected capital expenditures in 2024; and the expected costs and benefits of our ongoing optimization of our manufacturing operations, including the expected number of closings.
These forward-looking statements should be evaluated with consideration given to the many risks and uncertainties inherent in our business that could cause actual results and events to differ materially from those in the forward-looking statements. Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “estimate”, “should”, “predict” and similar terms or variations thereof. Such forward-looking statements are based on a series of expectations, assumptions, estimates and projections about the Company, are not guarantees of future results or performance, and involve significant risks, uncertainties and other factors, including assumptions and projections, for all forward periods. Our actual results may differ materially from any future results expressed or implied by such forward-looking statements.
Such risks, uncertainties and other factors include, among others, the following: (1) our substantial amount of indebtedness and its impact on our liquidity, credit ratings and ability to return capital to its shareholders; (2) our ability to successfully execute the next phase of our strategic transformation; (3) our ability to declare and pay dividends which is subject to certain considerations; (4) the impact of the outcomes of legal claims, disputes, regulatory investigations and litigation; (5) inflationary trends, including in the price of our input costs, such as raw materials, transportation and energy; (6) supply chain disruptions, geopolitical developments, including the
The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by the Company (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by the Company. Please refer to Part I. Item 1A., Risk Factors, of the Company’s Annual Report on Form 10-K filed with the SEC on February 28, 2024 for additional information regarding factors that could affect our results of operations, financial condition and liquidity.
We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results. Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release.
Use of Non-GAAP Financial Measures
We provide in this press release non-GAAP financial measures, including: (i) comparable currency neutral sales; (ii) adjusted operating EBITDA and comparable adjusted operating EBITDA; (iii) adjusted operating EBITDA margin; (iv) adjusted EPS ex amortization; (v) free cash flow; and (vi) net debt to credit adjusted EBITDA.
Our non-GAAP financial measures are defined below.
Currency Neutral metrics eliminate the effects that result from translating non-
Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization, interest expense, other (expense) income, net, and certain non-recurring or unusual items that are not part of recurring operations such as, restructuring and other charges, impairment of goodwill, gains (losses) on business disposals, loss on assets classified as held for sale, acquisition, divestiture and integration costs, strategic initiatives costs, regulatory costs and other items.
Adjusted EPS ex Amortization excludes the impact of non-operational items including, restructuring and other charges, impairment of goodwill, divestiture and integration costs, (gains) losses on business disposals, loss on assets classified as held for sale, gain on
Free Cash Flow is operating cash flow (i.e. cash flow from operations) less capital expenditures.
Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items.
Comparable results for the second quarter exclude the impact of divestitures and acquisitions.
These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.
The Company cannot reconcile its expected adjusted operating EBITDA under "Financial Guidance" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include but are not limited to acquisition, divestiture and integration costs, gains (losses) on business disposals, and regulatory costs.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
_______________________________________
1 Schedules at the end of this release contain reconciliations of reported GAAP to Non-GAAP metrics. See Use of Non-GAAP Financial Measures for explanations of our Non-GAAP metrics.
2 Comparable results for the second quarter exclude the impact of divestitures and acquisitions.
International Flavors & Fragrances Inc. Consolidated Statements of Income (Loss) (Amounts in millions except per share data) (Unaudited) |
|||||||||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||||||||
|
2024 |
|
2023 |
|
% Change |
|
2024 |
|
2023 |
|
% Change |
||||||||||
Net sales |
$ |
2,889 |
|
|
$ |
2,929 |
|
|
(1 |
)% |
|
$ |
5,788 |
|
|
$ |
5,956 |
|
|
(3 |
)% |
Cost of goods sold |
|
1,821 |
|
|
|
1,996 |
|
|
(9 |
)% |
|
|
3,696 |
|
|
|
4,059 |
|
|
(9 |
)% |
Gross profit |
|
1,068 |
|
|
|
933 |
|
|
14 |
% |
|
|
2,092 |
|
|
|
1,897 |
|
|
10 |
% |
Research and development expenses |
|
173 |
|
|
|
161 |
|
|
7 |
% |
|
|
339 |
|
|
|
322 |
|
|
5 |
% |
Selling and administrative expenses |
|
493 |
|
|
|
445 |
|
|
11 |
% |
|
|
983 |
|
|
|
899 |
|
|
9 |
% |
Amortization of acquisition-related intangibles |
|
153 |
|
|
|
172 |
|
|
(11 |
)% |
|
|
321 |
|
|
|
343 |
|
|
(6 |
)% |
Impairment of goodwill |
|
64 |
|
|
|
— |
|
|
NMF |
|
|
64 |
|
|
|
— |
|
|
NMF |
||
Restructuring and other charges |
|
2 |
|
|
|
7 |
|
|
(71 |
)% |
|
|
5 |
|
|
|
59 |
|
|
(92 |
)% |
(Gains) losses on sale of assets |
|
(8 |
) |
|
|
3 |
|
|
NMF |
|
|
(10 |
) |
|
|
(2 |
) |
|
NMF |
||
Operating profit |
|
191 |
|
|
|
145 |
|
|
32 |
% |
|
|
390 |
|
|
|
276 |
|
|
41 |
% |
Interest expense |
|
79 |
|
|
|
101 |
|
|
(22 |
)% |
|
|
162 |
|
|
|
201 |
|
|
(19 |
)% |
(Gains) losses on business disposals |
|
(368 |
) |
|
|
5 |
|
|
NMF |
|
|
(368 |
) |
|
|
19 |
|
|
NMF |
||
Loss on assets classified as held for sale |
|
282 |
|
|
|
— |
|
|
NMF |
|
|
282 |
|
|
|
— |
|
|
NMF |
||
Other expense (income), net |
|
15 |
|
|
|
(11 |
) |
|
(236 |
)% |
|
|
16 |
|
|
|
(8 |
) |
|
NMF |
|
Income before income taxes |
|
183 |
|
|
|
50 |
|
|
266 |
% |
|
|
298 |
|
|
|
64 |
|
|
NMF |
|
Provision for income taxes |
|
11 |
|
|
|
23 |
|
|
(52 |
)% |
|
|
65 |
|
|
|
45 |
|
|
44 |
% |
Net income |
|
172 |
|
|
|
27 |
|
|
NMF |
|
|
233 |
|
|
|
19 |
|
|
NMF |
||
Net income attributable to non-controlling interests |
|
2 |
|
|
|
— |
|
|
NMF |
|
|
3 |
|
|
|
1 |
|
|
200 |
% |
|
Net income attributable to IFF shareholders |
$ |
170 |
|
|
$ |
27 |
|
|
NMF |
|
$ |
230 |
|
|
$ |
18 |
|
|
NMF |
||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income per share - basic |
$ |
0.67 |
|
|
$ |
0.11 |
|
|
|
|
$ |
0.90 |
|
|
$ |
0.07 |
|
|
|
||
Net income per share - diluted |
$ |
0.66 |
|
|
$ |
0.11 |
|
|
|
|
$ |
0.90 |
|
|
$ |
0.07 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Average number of shares outstanding - basic |
|
255 |
|
|
|
255 |
|
|
|
|
|
255 |
|
|
|
255 |
|
|
|
||
Average number of shares outstanding - diluted |
|
256 |
|
|
|
255 |
|
|
|
|
|
256 |
|
|
|
255 |
|
|
|
||
NMF Not meaningful |
|||||||||||||||||||||
International Flavors & Fragrances Inc. Condensed Consolidated Balance Sheets (Amounts in millions) (Unaudited) |
|||||
|
June 30, |
|
December 31, |
||
|
2024 |
|
2023 |
||
Cash, cash equivalents, and restricted cash |
$ |
671 |
|
$ |
709 |
Receivables, net |
|
1,775 |
|
|
1,726 |
Inventories |
|
2,160 |
|
|
2,477 |
Other current assets |
|
3,543 |
|
|
1,381 |
Total current assets |
|
8,149 |
|
|
6,293 |
|
|
|
|
||
Property, plant and equipment, net |
|
3,763 |
|
|
4,240 |
Goodwill and other intangibles, net |
|
16,163 |
|
|
18,992 |
Other assets |
|
1,468 |
|
|
1,453 |
Total assets |
$ |
29,543 |
|
$ |
30,978 |
|
|
|
|
||
Short-term borrowings |
$ |
783 |
|
$ |
885 |
Other current liabilities |
|
2,642 |
|
|
2,873 |
Total current liabilities |
|
3,425 |
|
|
3,758 |
|
|
|
|
||
Long-term debt |
|
8,596 |
|
|
9,186 |
Non-current liabilities |
|
3,231 |
|
|
3,392 |
|
|
|
|
||
Shareholders' equity |
|
14,291 |
|
|
14,642 |
Total liabilities and shareholders' equity |
$ |
29,543 |
|
$ |
30,978 |
International Flavors & Fragrances Inc. Consolidated Statements of Cash Flows (Amounts in millions) (Unaudited) |
|||||||
|
Six Months Ended June 30, |
||||||
|
2024 |
|
2023 |
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
233 |
|
|
$ |
19 |
|
Adjustments to reconcile to net cash provided by operating activities |
|
|
|
||||
Depreciation and amortization |
|
524 |
|
|
|
563 |
|
Deferred income taxes |
|
(77 |
) |
|
|
(27 |
) |
Loss on assets classified as held for sale |
|
282 |
|
|
|
— |
|
Gains on sale of assets |
|
(10 |
) |
|
|
(2 |
) |
(Gains) Losses on business disposals |
|
(368 |
) |
|
|
19 |
|
Stock-based compensation |
|
43 |
|
|
|
32 |
|
Pension contributions |
|
(11 |
) |
|
|
(18 |
) |
Impairment of goodwill |
|
64 |
|
|
|
— |
|
Inventory write-down |
|
— |
|
|
|
44 |
|
Changes in assets and liabilities: |
|
|
|
||||
Trade receivables |
|
(293 |
) |
|
|
(70 |
) |
Inventories |
|
4 |
|
|
|
333 |
|
Accounts payable |
|
54 |
|
|
|
(92 |
) |
Accruals for incentive compensation |
|
18 |
|
|
|
(77 |
) |
Other current payables and accrued expenses |
|
(78 |
) |
|
|
(248 |
) |
Other assets/liabilities, net |
|
(49 |
) |
|
|
(101 |
) |
Net cash provided by operating activities |
|
336 |
|
|
|
375 |
|
Cash flows from investing activities: |
|
|
|
||||
Additions to property, plant and equipment |
|
(200 |
) |
|
|
(290 |
) |
Proceeds from disposal of assets |
|
16 |
|
|
|
21 |
|
Net proceeds received from business divestitures |
|
848 |
|
|
|
821 |
|
Net cash provided by investing activities |
|
664 |
|
|
|
552 |
|
Cash flows from financing activities: |
|
|
|
||||
Cash dividends paid to shareholders |
|
(309 |
) |
|
|
(413 |
) |
Decrease in revolving credit facility and short-term borrowings |
|
— |
|
|
|
(100 |
) |
Net borrowings of commercial paper (maturities less than three months) |
|
189 |
|
|
|
(28 |
) |
Principal payments of debt |
|
(849 |
) |
|
|
(300 |
) |
Deferred and contingent consideration paid |
|
(36 |
) |
|
|
(6 |
) |
Withholding tax paid on stock-based compensation |
|
(14 |
) |
|
|
(11 |
) |
Other, net |
|
(4 |
) |
|
|
(8 |
) |
Net cash used in financing activities |
|
(1,023 |
) |
|
|
(866 |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
(38 |
) |
|
|
39 |
|
Net change in cash, cash equivalents and restricted cash |
|
(61 |
) |
|
|
100 |
|
Cash, cash equivalents and restricted cash at beginning of year |
|
735 |
|
|
|
552 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
674 |
|
|
$ |
652 |
|
The following table reconciles cash, cash equivalents and restricted cash between the Company's statement of cash flows for the periods ended June 30, 2024 and June 30, 2023 to the amounts reported on the Company's balance sheet:
AMOUNTS IN MILLIONS |
June 30, 2024 |
|
December 31, 2023 |
|
June 30, 2023 |
|
December 31, 2022 |
||||
Current assets |
|
|
|
|
|
|
|
||||
Cash and cash equivalents |
$ |
671 |
|
$ |
703 |
|
$ |
638 |
|
$ |
483 |
Cash and cash equivalents included in Assets held for sale |
|
3 |
|
|
26 |
|
|
3 |
|
|
52 |
Restricted cash |
|
— |
|
|
6 |
|
|
11 |
|
|
10 |
Non-current assets |
|
|
|
|
|
|
|
||||
Restricted cash included in Other assets |
|
— |
|
|
— |
|
|
— |
|
|
7 |
Cash, cash equivalents and restricted cash |
$ |
674 |
|
$ |
735 |
|
$ |
652 |
|
$ |
552 |
International Flavors & Fragrances Inc. Reportable Segment Performance (Amounts in millions) (Unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net Sales |
|
|
|
|
|
|
|
||||||||
Nourish |
$ |
1,478 |
|
|
$ |
1,564 |
|
|
$ |
2,974 |
|
|
$ |
3,217 |
|
Health & Biosciences |
|
558 |
|
|
|
522 |
|
|
|
1,089 |
|
|
|
1,035 |
|
Scent |
|
603 |
|
|
|
592 |
|
|
|
1,248 |
|
|
|
1,200 |
|
Pharma Solutions |
|
250 |
|
|
|
251 |
|
|
|
477 |
|
|
|
504 |
|
Consolidated |
$ |
2,889 |
|
|
$ |
2,929 |
|
|
$ |
5,788 |
|
|
$ |
5,956 |
|
Segment Adjusted Operating EBITDA |
|
|
|
|
|
|
|
||||||||
Nourish |
$ |
232 |
|
|
$ |
181 |
|
|
$ |
448 |
|
|
$ |
389 |
|
Health & Biosciences |
|
165 |
|
|
|
145 |
|
|
|
324 |
|
|
|
276 |
|
Scent |
|
137 |
|
|
|
117 |
|
|
|
294 |
|
|
|
222 |
|
Pharma Solutions |
|
54 |
|
|
|
67 |
|
|
|
100 |
|
|
|
126 |
|
Total |
|
588 |
|
|
|
510 |
|
|
|
1,166 |
|
|
|
1,013 |
|
Depreciation & Amortization |
|
(246 |
) |
|
|
(287 |
) |
|
|
(524 |
) |
|
|
(563 |
) |
Interest Expense |
|
(79 |
) |
|
|
(101 |
) |
|
|
(162 |
) |
|
|
(201 |
) |
Other (Expense) Income, net |
|
(15 |
) |
|
|
11 |
|
|
|
(16 |
) |
|
|
8 |
|
Restructuring and Other Charges |
|
(2 |
) |
|
|
(7 |
) |
|
|
(5 |
) |
|
|
(59 |
) |
Impairment of Goodwill |
|
(64 |
) |
|
|
— |
|
|
|
(64 |
) |
|
|
— |
|
Gains (Losses) on Business Disposals |
|
368 |
|
|
|
(5 |
) |
|
|
368 |
|
|
|
(19 |
) |
Loss on Assets Classified as Held for Sale |
|
(282 |
) |
|
|
— |
|
|
|
(282 |
) |
|
|
— |
|
Acquisition, Divestiture and Integration Costs |
|
(59 |
) |
|
|
(45 |
) |
|
|
(117 |
) |
|
|
(76 |
) |
Strategic Initiatives Costs |
|
(12 |
) |
|
|
(9 |
) |
|
|
(16 |
) |
|
|
(22 |
) |
Regulatory Costs |
|
(19 |
) |
|
|
(14 |
) |
|
|
(54 |
) |
|
|
(19 |
) |
Other |
|
5 |
|
|
|
(3 |
) |
|
|
4 |
|
|
|
2 |
|
Income Before Taxes |
$ |
183 |
|
|
$ |
50 |
|
|
$ |
298 |
|
|
$ |
64 |
|
Segment Adjusted Operating EBITDA Margin |
|
|
|
|
|
|
|
||||||||
Nourish |
|
15.7 |
% |
|
|
11.6 |
% |
|
|
15.1 |
% |
|
|
12.1 |
% |
Health & Biosciences |
|
29.6 |
% |
|
|
27.8 |
% |
|
|
29.8 |
% |
|
|
26.7 |
% |
Scent |
|
22.7 |
% |
|
|
19.8 |
% |
|
|
23.6 |
% |
|
|
18.5 |
% |
Pharma Solutions |
|
21.6 |
% |
|
|
26.7 |
% |
|
|
21.0 |
% |
|
|
25.0 |
% |
Consolidated |
|
20.4 |
% |
|
|
17.4 |
% |
|
|
20.1 |
% |
|
|
17.0 |
% |
International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Gross Profit |
|||||||
|
Second Quarter |
||||||
(DOLLARS IN MILLIONS) |
2024 |
|
2023 |
||||
Reported (GAAP) |
$ |
1,068 |
|
$ |
933 |
||
Adjusted (Non-GAAP) |
$ |
1,068 |
|
$ |
933 |
||
Reconciliation of Selling and Administrative Expenses |
|||||||
|
Second Quarter |
||||||
(DOLLARS IN MILLIONS) |
2024 |
|
2023 |
||||
Reported (GAAP) |
$ |
493 |
|
|
$ |
445 |
|
Acquisition, Divestiture and Integration Costs (e) |
|
(59 |
) |
|
|
(45 |
) |
Strategic Initiatives Costs (g) |
|
(12 |
) |
|
|
(9 |
) |
Regulatory Costs (h) |
|
(19 |
) |
|
|
(14 |
) |
Other (i) |
|
(2 |
) |
|
|
— |
|
Adjusted (Non-GAAP) |
$ |
401 |
|
|
$ |
377 |
|
International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Net Income (Loss) and EPS |
|||||||||||||||||||||||||||||||
|
Second Quarter |
||||||||||||||||||||||||||||||
|
2024 |
|
2023 |
||||||||||||||||||||||||||||
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) |
Income
|
|
Provision
|
|
Net income
|
|
Diluted
|
|
Income
|
|
Provision
|
|
Net income
|
|
Diluted
|
||||||||||||||||
Reported (GAAP) |
$ |
183 |
|
|
$ |
11 |
|
|
$ |
170 |
|
|
$ |
0.66 |
|
|
$ |
50 |
|
|
$ |
23 |
|
|
$ |
27 |
|
|
$ |
0.11 |
|
Restructuring and Other Charges (a) |
|
2 |
|
|
|
— |
|
|
|
2 |
|
|
|
0.01 |
|
|
|
7 |
|
|
|
4 |
|
|
|
3 |
|
|
|
0.02 |
|
Impairment of Goodwill (b) |
|
64 |
|
|
|
— |
|
|
|
64 |
|
|
|
0.25 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
(Gains) Losses on Business Disposals (c) |
|
(368 |
) |
|
|
(23 |
) |
|
|
(345 |
) |
|
|
(1.35 |
) |
|
|
5 |
|
|
|
(8 |
) |
|
|
13 |
|
|
|
0.05 |
|
Loss on Assets Classified as Held for Sale (d) |
|
282 |
|
|
|
58 |
|
|
|
224 |
|
|
|
0.87 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Acquisition, Divestiture and Integration Costs (e) |
|
56 |
|
|
|
10 |
|
|
|
46 |
|
|
|
0.18 |
|
|
|
45 |
|
|
|
7 |
|
|
|
38 |
|
|
|
0.15 |
|
Gain on China Facility Relocation (f) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(22 |
) |
|
|
(6 |
) |
|
|
(16 |
) |
|
|
(0.06 |
) |
Strategic Initiatives Costs (g) |
|
12 |
|
|
|
3 |
|
|
|
9 |
|
|
|
0.04 |
|
|
|
9 |
|
|
|
2 |
|
|
|
7 |
|
|
|
0.03 |
|
Regulatory Costs (h) |
|
19 |
|
|
|
4 |
|
|
|
15 |
|
|
|
0.06 |
|
|
|
14 |
|
|
|
3 |
|
|
|
11 |
|
|
|
0.04 |
|
Other (i) |
|
(5 |
) |
|
|
(3 |
) |
|
|
(2 |
) |
|
|
(0.02 |
) |
|
|
3 |
|
|
|
— |
|
|
|
3 |
|
|
|
0.01 |
|
Adjusted (Non-GAAP) |
$ |
245 |
|
|
$ |
60 |
|
|
$ |
183 |
|
|
$ |
0.71 |
|
|
$ |
111 |
|
|
$ |
25 |
|
|
$ |
86 |
|
|
$ |
0.34 |
|
Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization |
|||||
|
Second Quarter |
||||
(DOLLARS AND SHARE AMOUNTS IN MILLIONS) |
2024 |
|
2023 |
||
Numerator |
|
|
|
||
Adjusted (Non-GAAP) Net Income |
$ |
183 |
|
$ |
86 |
Amortization of Acquisition related Intangible Assets |
|
153 |
|
|
172 |
Tax impact on Amortization of Acquisition related Intangible Assets (j) |
|
38 |
|
|
39 |
Amortization of Acquisition related Intangible Assets, net of tax (m) |
|
115 |
|
|
133 |
Adjusted (Non-GAAP) Net Income ex. Amortization |
$ |
298 |
|
$ |
219 |
|
|
|
|
||
Denominator |
|
|
|
||
Weighted average shares assuming dilution (diluted) |
|
256 |
|
|
255 |
Adjusted (Non-GAAP) EPS ex. Amortization |
$ |
1.16 |
|
$ |
0.86 |
(a) |
For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts. |
|
(b) |
Represents costs related to the impairment of goodwill related to the Pharma Solutions disposal group. |
|
(c) |
For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business. For 2023, primarily represents losses recognized as part of the sale of a portion of the Savory Solutions business. |
|
(d) |
Represents the loss recognized on assets classified as held for sale of the Pharma Solutions disposal group. |
|
(e) |
For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2024 and 2023, tax expenses for business divestiture costs included establishments of deferred tax liabilities related to planned sales of businesses.
For the three months ended June 30, 2024, business divestiture and integration costs were approximately |
|
(f) |
For 2023, represents gain recognized from the completion of the relocation of a facility in |
|
(g) |
Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. |
|
(h) |
Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. |
|
(i) |
Represents (gains) losses from sale of assets, executive employee separation costs and costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees. |
|
(j) |
The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at |
|
(k) |
For the three months ended June 30, 2024, reported and adjusted net income are each decreased by income attributable to non-controlling interest of |
|
(l) |
The sum of these items does not foot due to rounding. |
|
(m) |
Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |
International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Gross Profit |
|||||||
|
Second Quarter Year-to-Date |
||||||
(DOLLARS IN MILLIONS) |
2024 |
|
2023 |
||||
Reported (GAAP) |
$ |
2,092 |
|
$ |
1,897 |
||
Acquisition, Divestiture and Integration Costs (e) |
|
1 |
|
|
— |
||
Adjusted (Non-GAAP) |
$ |
2,093 |
|
$ |
1,897 |
||
Reconciliation of Selling and Administrative Expenses |
|||||||
|
Second Quarter Year-to-Date |
||||||
(DOLLARS IN MILLIONS) |
2024 |
|
2023 |
||||
Reported (GAAP) |
$ |
983 |
|
|
$ |
899 |
|
Acquisition, Divestiture and Integration Costs (e) |
|
(116 |
) |
|
|
(76 |
) |
Strategic Initiatives Costs (g) |
|
(16 |
) |
|
|
(22 |
) |
Regulatory Costs (h) |
|
(54 |
) |
|
|
(19 |
) |
Other (i) |
|
(5 |
) |
|
|
— |
|
Adjusted (Non-GAAP) |
$ |
792 |
|
|
$ |
782 |
|
International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Net Income (Loss) and EPS |
|||||||||||||||||||||||||||||||
|
Second Quarter Year-to-Date |
||||||||||||||||||||||||||||||
|
2024 |
|
2023 |
||||||||||||||||||||||||||||
(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) |
Income
|
|
Provision
|
|
Net income
|
|
Diluted
|
|
Income
|
|
Provision
|
|
Net income
|
|
Diluted
|
||||||||||||||||
Reported (GAAP) |
$ |
298 |
|
|
$ |
65 |
|
|
$ |
230 |
|
|
$ |
0.90 |
|
|
$ |
64 |
|
|
$ |
45 |
|
|
$ |
18 |
|
|
$ |
0.07 |
|
Restructuring and Other Charges (a) |
|
5 |
|
|
|
1 |
|
|
|
4 |
|
|
|
0.02 |
|
|
|
59 |
|
|
|
16 |
|
|
|
43 |
|
|
|
0.17 |
|
Impairment of Goodwill (b) |
|
64 |
|
|
|
— |
|
|
|
64 |
|
|
|
0.25 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
(Gains) Losses on Business Disposals (c) |
|
(368 |
) |
|
|
(23 |
) |
|
|
(345 |
) |
|
|
(1.35 |
) |
|
|
19 |
|
|
|
(5 |
) |
|
|
24 |
|
|
|
0.09 |
|
Loss on Assets Classified as Held for Sale (d) |
|
282 |
|
|
|
58 |
|
|
|
224 |
|
|
|
0.87 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Acquisition, Divestiture and Integration Costs (e) |
|
114 |
|
|
|
3 |
|
|
|
111 |
|
|
|
0.44 |
|
|
|
76 |
|
|
|
— |
|
|
|
76 |
|
|
|
0.30 |
|
Gain on China Facility Relocation (f) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(22 |
) |
|
|
(6 |
) |
|
|
(16 |
) |
|
|
(0.06 |
) |
Strategic Initiatives Costs (g) |
|
16 |
|
|
|
4 |
|
|
|
12 |
|
|
|
0.05 |
|
|
|
22 |
|
|
|
5 |
|
|
|
17 |
|
|
|
0.07 |
|
Regulatory Costs (h) |
|
54 |
|
|
|
8 |
|
|
|
46 |
|
|
|
0.18 |
|
|
|
19 |
|
|
|
4 |
|
|
|
15 |
|
|
|
0.06 |
|
Other (i) |
|
(4 |
) |
|
|
(3 |
) |
|
|
(1 |
) |
|
|
(0.02 |
) |
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
— |
|
Adjusted (Non-GAAP) |
$ |
461 |
|
|
$ |
113 |
|
|
$ |
345 |
|
|
$ |
1.34 |
|
|
$ |
235 |
|
|
$ |
58 |
|
|
$ |
176 |
|
|
$ |
0.69 |
|
Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization |
|||||
|
Second Quarter Year-to-Date |
||||
(DOLLARS AND SHARE AMOUNTS IN MILLIONS) |
2024 |
|
2023 |
||
Numerator |
|
|
|
||
Adjusted (Non-GAAP) Net Income |
$ |
345 |
|
$ |
176 |
Amortization of Acquisition related Intangible Assets |
|
321 |
|
|
343 |
Tax impact on Amortization of Acquisition related Intangible Assets (j) |
|
79 |
|
|
78 |
Amortization of Acquisition related Intangible Assets, net of tax (m) |
|
242 |
|
|
265 |
Adjusted (Non-GAAP) Net Income ex. Amortization |
$ |
587 |
|
$ |
441 |
|
|
|
|
||
Denominator |
|
|
|
||
Weighted average shares assuming dilution (diluted) |
|
256 |
|
|
255 |
Adjusted (Non-GAAP) EPS ex. Amortization |
$ |
2.29 |
|
$ |
1.72 |
(a) |
For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts. |
|
(b) |
Represents costs related to the impairment of goodwill related to the Pharma Solutions disposal group. |
|
(c) |
For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business. For 2023, primarily represents losses recognized as part of the sale of a portion of the Savory Solutions business. |
|
(d) |
Represents the loss recognized on assets classified as held for sale of the Pharma Solutions disposal group. |
|
(e) |
For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2024 and 2023, tax expenses for business divestiture costs included establishments of deferred tax liabilities related to planned sales of businesses.
For the three months ended June 30, 2024, business divestiture and integration costs were approximately |
|
(f) |
For 2023, represents gain recognized from the completion of the relocation of a facility in |
|
(g) |
Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. |
|
(h) |
Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. |
|
(i) |
Represents (gains) losses from sale of assets, executive employee separation costs and costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees. |
|
(j) |
The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at |
|
(k) |
For the three months ended June 30, 2024, reported and adjusted net income are each decreased by income attributable to non-controlling interest of |
|
(l) |
The sum of these items does not foot due to rounding. |
|
(m) |
Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |
International Flavors & Fragrances Inc.
Debt Covenants
(Amounts in millions)
(Unaudited)
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Credit Adjusted EBITDA to Net Loss |
|||
(DOLLARS IN MILLIONS) |
Twelve Months Ended
|
||
Net loss |
$ |
(2,355 |
) |
Interest expense(1) |
|
341 |
|
Income taxes |
|
65 |
|
Depreciation and amortization |
|
1,103 |
|
Specified items(2) |
|
3,030 |
|
Non-cash items(3) |
|
11 |
|
Credit Adjusted EBITDA |
$ |
2,195 |
|
| ____________________________________ | ||
| (1) | Certain adjustments were made to interest expense associated with our cash pooling arrangements for the third and fourth quarters of 2023. |
|
| (2) | Specified items consisted of restructuring and other charges, impairment of goodwill, acquisition, divestiture and integration costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations. |
|
| (3) | Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, loss on assets classified as held for sale, write-down of inventory related to Locust Bean Kernel and stock-based compensation. |
|
Net Debt to Total Debt |
|||
(DOLLARS IN MILLIONS) |
June 30, 2024 |
||
Total debt(1) |
$ |
9,404 |
|
Adjustments: |
|
||
Cash and cash equivalents(2) |
|
674 |
|
Net debt |
$ |
8,730 |
|
| ___________________________ | ||
| (1) | Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations. |
|
| (2) |
Cash and cash equivalents included approximately |
|
International Flavors & Fragrances Inc.
Comparable Reportable Segment Performance
(Amounts in millions)
(Unaudited)
The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net Sales |
|
|
|
|
|
|
|
||||||||
Nourish(1) |
$ |
1,478 |
|
|
$ |
1,470 |
|
|
$ |
2,974 |
|
|
$ |
2,985 |
|
Health & Biosciences |
|
558 |
|
|
|
522 |
|
|
|
1,089 |
|
|
|
1,035 |
|
Scent(2) |
|
603 |
|
|
|
547 |
|
|
|
1,248 |
|
|
|
1,135 |
|
Pharma Solutions |
|
250 |
|
|
|
251 |
|
|
|
477 |
|
|
|
504 |
|
Consolidated |
$ |
2,889 |
|
|
$ |
2,790 |
|
|
$ |
5,788 |
|
|
$ |
5,659 |
|
Segment Adjusted Operating EBITDA |
|
|
|
|
|
|
|
||||||||
Nourish(1) |
$ |
232 |
|
|
$ |
171 |
|
|
$ |
448 |
|
|
$ |
363 |
|
Health & Biosciences |
|
165 |
|
|
|
145 |
|
|
|
324 |
|
|
|
276 |
|
Scent(2) |
|
137 |
|
|
|
99 |
|
|
|
294 |
|
|
|
200 |
|
Pharma Solutions |
|
54 |
|
|
|
67 |
|
|
|
100 |
|
|
|
126 |
|
Total |
|
588 |
|
|
|
482 |
|
|
|
1,166 |
|
|
|
965 |
|
Depreciation & Amortization |
|
(246 |
) |
|
|
(287 |
) |
|
|
(524 |
) |
|
|
(563 |
) |
Interest Expense |
|
(79 |
) |
|
|
(101 |
) |
|
|
(162 |
) |
|
|
(201 |
) |
Other (Expense) Income, net |
|
(15 |
) |
|
|
11 |
|
|
|
(16 |
) |
|
|
8 |
|
Restructuring and Other Charges |
|
(2 |
) |
|
|
(7 |
) |
|
|
(5 |
) |
|
|
(59 |
) |
Impairment of Goodwill |
|
(64 |
) |
|
|
— |
|
|
|
(64 |
) |
|
|
— |
|
Gains (Losses) on Business Disposals |
|
368 |
|
|
|
(5 |
) |
|
|
368 |
|
|
|
(19 |
) |
Loss on Assets Classified as Held for Sale |
|
(282 |
) |
|
|
— |
|
|
|
(282 |
) |
|
|
— |
|
Acquisition, Divestiture and Integration Costs |
|
(59 |
) |
|
|
(45 |
) |
|
|
(117 |
) |
|
|
(76 |
) |
Strategic Initiatives Costs |
|
(12 |
) |
|
|
(9 |
) |
|
|
(16 |
) |
|
|
(22 |
) |
Regulatory Costs |
|
(19 |
) |
|
|
(14 |
) |
|
|
(54 |
) |
|
|
(19 |
) |
Other |
|
5 |
|
|
|
(3 |
) |
|
|
4 |
|
|
|
2 |
|
Impact of Business Divestitures(3) |
|
— |
|
|
|
28 |
|
|
|
— |
|
|
|
48 |
|
Income Before Taxes |
$ |
183 |
|
|
$ |
50 |
|
|
$ |
298 |
|
|
$ |
64 |
|
Segment Adjusted Operating EBITDA Margin |
|
|
|
|
|
|
|
||||||||
Nourish |
|
15.7 |
% |
|
|
11.6 |
% |
|
|
15.1 |
% |
|
|
12.2 |
% |
Health & Biosciences |
|
29.6 |
% |
|
|
27.8 |
% |
|
|
29.8 |
% |
|
|
26.7 |
% |
Scent |
|
22.7 |
% |
|
|
18.1 |
% |
|
|
23.6 |
% |
|
|
17.6 |
% |
Pharma Solutions |
|
21.6 |
% |
|
|
26.7 |
% |
|
|
21.0 |
% |
|
|
25.0 |
% |
Consolidated |
|
20.4 |
% |
|
|
17.3 |
% |
|
|
20.1 |
% |
|
|
17.1 |
% |
| _________________________ | ||
(1) |
Nourish sales and segment adjusted operating EBITDA for the three and six months ended June 30, 2023 exclude the results of the portion of the Savory Solutions business and Sonarome business that were divested to present fully comparable scenarios. The divestitures were completed on May 31, 2023 and December 1, 2023, respectively. |
|
(2) |
Scent sales and segment adjusted operating EBITDA for the three and six months ended June 30, 2023 exclude the results of the Flavor Specialty Ingredients business and Cosmetic Ingredients business that were divested to present fully comparable scenarios. The divestitures were completed on August 1, 2023 and April 2, 2024, respectively. |
|
(3) |
Amounts exclude the results of the portion of the Savory Solutions business, Flavor Specialty Ingredients business, Sonarome business, and Cosmetic Ingredients business that were divested in the second quarter of 2023 (May 31, 2023), third quarter of 2023 (August 1, 2023), fourth quarter of 2023 (December 1, 2023), and second quarter of 2024 (April 2, 2024), respectively, to present fully comparable scenarios. |
|
International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation Comparable Foreign Exchange Impact (Unaudited) |
||||||
|
|
|
||||
Q2 Nourish |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
(5)% |
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
Q2 Health & Biosciences |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
|
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
Q2 Scent |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
|
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
Q2 Pharma Solutions |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
|
|
(19)% |
|
(5.1)% |
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
(19)% |
|
(5.1)% |
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
Q2 Consolidated |
|
Sales |
|
Adjusted Operating EBITDA |
|
Adjusted Operating EBITDA Margin |
% Change - Reported |
|
(1)% |
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
| _____________________ |
|
|
|
|
|
|
Note: The sum of these items may not foot due to rounding. |
||||||
International Flavors & Fragrances Inc. GAAP to Non-GAAP Reconciliation Comparable Foreign Exchange Impact (Unaudited) |
||||||
|
|
|
||||
YTD Nourish |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
(8)% |
|
|
|
|
Portfolio Impact |
|
|
|
|
|
(0.1)% |
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD Health & Biosciences |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
|
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD Scent |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
|
|
|
|
|
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD Pharma Solutions |
|
Sales |
|
Segment Adjusted Operating EBITDA |
|
Segment Adjusted Operating EBITDA Margin |
% Change - Reported |
|
(5)% |
|
(21)% |
|
(4.0)% |
Portfolio Impact |
|
|
|
|
|
|
% Change - Comparable |
|
(5)% |
|
(21)% |
|
(4.0)% |
Currency Impact |
|
(1)% |
|
|
|
|
% Change - Currency Neutral |
|
(6)% |
|
|
|
|
|
|
|
|
|
|
|
YTD Consolidated |
|
Sales |
|
Adjusted Operating EBITDA |
|
Adjusted Operating EBITDA Margin |
% Change - Reported |
|
(3)% |
|
|
|
|
Portfolio Impact |
|
|
|
|
|
(0.1)% |
% Change - Comparable |
|
|
|
|
|
|
Currency Impact |
|
|
|
|
|
|
% Change - Currency Neutral |
|
|
|
|
|
|
| ______________________ |
|
|
|
|
|
|
Note: The sum of these items may not foot due to rounding. |
||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806419214/en/
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
Source: IFF
FAQ
What were IFF's Q2 2024 financial results?
How did IFF's segments perform in Q2 2024?
What is IFF's updated guidance for full-year 2024?
How did IFF's stock symbol (IFF) perform in terms of earnings per share in Q2 2024?
